Compare ELPC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELPC | PRAX |
|---|---|---|
| Founded | 1954 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 9.6B |
| IPO Year | N/A | 2020 |
| Metric | ELPC | PRAX |
|---|---|---|
| Price | $11.47 | $297.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $572.13 |
| AVG Volume (30 Days) | 228.2K | ★ 328.9K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 5.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.11 | $6,395.88 |
| P/E Ratio | $77.44 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.13 | $26.70 |
| 52 Week High | $11.85 | $354.87 |
| Indicator | ELPC | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 57.25 | 39.85 |
| Support Level | $8.88 | $290.36 |
| Resistance Level | $11.76 | $322.32 |
| Average True Range (ATR) | 0.30 | 17.69 |
| MACD | -0.04 | -5.16 |
| Stochastic Oscillator | 68.30 | 14.99 |
Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power sale, Services, and Holding. The majority of its revenue is generated from the Power generation and transmission segment under which it produces electricity from hydraulic, wind, and thermal projects and provides services of transmission and transformation of electric power and other related services.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.